Advanced BiomedADVB +5.42%12 Cash Ratio is 1.83 as of Mar. 2026, which is 87% above its 10-year median of 0.98. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 210 Medical Diagnostics & Research companies, Advanced Biomed ranks better than 69.52% on this metric.
Advanced Biomed has a Cash Ratio of 1.83. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Advanced Biomed's Cash Ratio or its related term are showing as below:
ADVB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.61 Med: 0.98 Max: 2.36
Current: 1.83
During the past 5 years, Advanced Biomed's highest Cash Ratio was 2.36. The lowest was 0.61. And the median was 0.98.
ADVB's Cash Ratio is ranked better than 69.52% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.965
vs ADVB: 1.83
Advanced Biomed (NAS:ADVB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Advanced Biomed Cash Ratio Related Terms
Advanced Biomed Cash Ratio Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Advanced Biomed's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Biomed (ADVB) has a Cash Ratio of 1.83 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Advanced Biomed and its competitors. This is 87% above median its historical median of 0.98. Over the past decade, Advanced Biomed's Cash Ratio has ranged from 0.61 to 2.36. According to the industry distribution chart, Advanced Biomed ranks #64 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 30.5%.
Is Advanced Biomed's Cash Ratio too high?
Advanced Biomed's current Cash Ratio of 1.83 is 87% above median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 2.36. The Medical Diagnostics & Research industry median Cash Ratio is 0.97. Advanced Biomed's value of 1.83 is 89.6% above this industry median. Based on the distribution chart, Advanced Biomed ranks #64 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Cash Ratio compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #64 out of 210 companies for Cash Ratio. This puts Advanced Biomed in the upper half of its industry. The industry median Cash Ratio is 0.97. Advanced Biomed's value of 1.83 is 89.6% above this benchmark. Historically, Advanced Biomed's own Cash Ratio has ranged from 0.61 to 2.36 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 0.97, Advanced Biomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.97, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Biomed's current Cash Ratio of 1.83 is 89.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current Cash Ratio is 1.83, which is 87% above median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Cash Ratio of 1.83. The current Cash Ratio is 1.83, which is 87% above median its 10-year median of 0.98 and 89.6% above the Medical Diagnostics & Research industry median of 0.97. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Cash Ratio is 1.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
